Skip to main content

Advertisement

SpringerLink
Log in

Valvular Heart Disease in Antiphospholipid Syndrome

  • ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %. The definition is based on the presence of thickening or vegetation of the valves (mainly mitral and aortic) as described by Libman and Sacks for patients with systemic lupus erythematosus (SLE). Transthoracic and/or transoesophageal echocardiography (TTE and TEE, respectively) enable early and accurate diagnosis and help avoid misdiagnosis as rheumatic valve disease. The presence of antiphospholipid antibodies (aPL) in SLE patients is associated with a threefold greater risk of HVD, confirming the crucial importance of these antibodies in the pathogenic process, leading to thrombotic manifestations on valves because of hypercoagulability. Natural history is characterized by worsening of HVD over time with an increased risk for stroke. APS patients undergoing valve-replacement surgery are at high risk of thrombotic and bleeding complications. Thus aPL-associated HVD has affects clinical management of APS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  PubMed  CAS  Google Scholar 

  2. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737–40.

    Article  PubMed  CAS  Google Scholar 

  3. Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64:1–10.

    Article  PubMed  Google Scholar 

  4. • Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic Antiphospholipid Syndrome (APS) and non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20:165–73. This recent consensus report reviewed a large number of studies performed on patients with aPL and HVD and gave recommendations for management of these patients.

    Article  PubMed  CAS  Google Scholar 

  5. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.

    Article  PubMed  Google Scholar 

  6. Menard GE. Establishing the diagnosis of Libman–Sacks endocarditis in systemic lupus erythematosus. J Gen Intern Med. 2008;23:883–6.

    Article  PubMed  Google Scholar 

  7. Taguchi S, Hashimoto K, Sakamoto Y, Okuyama H, Ishii S. A case of mitral valve plasty for Libman–Sacks endocarditis mimicking a cardiac tumor. J Thorac Cardiovasc Surg. 2006;132:1465–7.

    Article  PubMed  Google Scholar 

  8. Ford SE, Lillicrap D, Brunet D, Ford P. Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic ‘rheumatic type’ valvular heart disease. Arch Pathol Lab Med. 1989;113:350–3.

    PubMed  CAS  Google Scholar 

  9. Espinola-Zavaleta N, Amigo MC, Vargas-Barron J, et al. Two- and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease. Lupus. 2001;10:511–3.

    Article  PubMed  CAS  Google Scholar 

  10. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701–37.

    Article  Google Scholar 

  11. Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985–2000. Mayo Clin Proc. 2001;76:1204–12.

    Article  PubMed  CAS  Google Scholar 

  12. Piette JC, Amoura Z, Papo T. Valvular heart disease and systemic lupus erythematosus. N Engl J Med. 1997;336:1324. author reply 1324–5.

    Article  PubMed  CAS  Google Scholar 

  13. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918–25.

    Article  PubMed  CAS  Google Scholar 

  14. Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus. 2003;12:805–12.

    Article  PubMed  CAS  Google Scholar 

  15. Perez-Villa F, Font J, Azqueta M, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum. 2005;53:460–7.

    Article  PubMed  Google Scholar 

  16. Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95:1441–7.

    Article  PubMed  Google Scholar 

  17. Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology. 2007;108:331–7.

    Article  PubMed  Google Scholar 

  18. •• Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124:215–24. This meta-analysis of all available echocardiographic studies clearly demonstrated that for SLE patients with aPL, compared with those without, the risk of HVD, including Libman–Sacks endocarditis, was increased threefold.

    Article  PubMed  CAS  Google Scholar 

  19. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke. 2005;36:592–6.

    Article  PubMed  Google Scholar 

  20. Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus. 2000;9:406–12.

    Article  PubMed  CAS  Google Scholar 

  21. Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005;96:574–9.

    Article  PubMed  Google Scholar 

  22. Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol. 2004;31:2402–7.

    PubMed  Google Scholar 

  23. Petri MA. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J Rheumatol. 2004;31:2329–30.

    PubMed  Google Scholar 

  24. Ziporen L, Goldberg I, Arad M, et al. Libman–Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996;5:196–205.

    Article  PubMed  CAS  Google Scholar 

  25. Blank M, Shani A, Goldberg I, et al. Libman–Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res. 2004;114:589–92.

    Article  PubMed  CAS  Google Scholar 

  26. Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Revisiting Libman–Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009;36:126–30.

    Article  PubMed  Google Scholar 

  27. Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92:714–5.

    Article  PubMed  Google Scholar 

  28. Liestol S, Sandset PM, Mowinckel MC, Wisloff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost. 2007;5:2204–10.

    Article  PubMed  CAS  Google Scholar 

  29. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–87.

    Article  PubMed  CAS  Google Scholar 

  30. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman–Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120:636–42.

    Article  PubMed  Google Scholar 

  31. Amoroso A, Cacciapaglia F, De Castro S, et al. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol. 2006;24:287–94.

    PubMed  CAS  Google Scholar 

  32. Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol. 2001;30:235–41.

    Article  PubMed  CAS  Google Scholar 

  33. • Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010;19:575–82. This study reports results from a relatively small cohort with a long follow-up and reports the incidence of new valvular involvement over time.

    Article  PubMed  CAS  Google Scholar 

  34. •• Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32. This study reported epidemiologic data of the largest multicenter cohort of APS patients ever published and reported results for HVD. However, because of the multicentre design the diagnostic workout was heterogeneous.

    Article  PubMed  CAS  Google Scholar 

  35. Tektonidou MG, Kampolis CF, Moyssakis I, et al. Myocardial dysfunction and valvulopathy worsens with time in patients with antiphospholipid syndrome: a 10-year follow-up study. [Abstract 1738]. Presented at the American College of Rheumatology / ARHP Annual Meeting. Washington, USA; November 10–14, 2012.

  36. Vinales KL, Gopalan RS, Lanza LA, Lester SJ, Chaliki HP. Unusual case of nonbacterial thrombotic endocarditis attributable to primary antiphospholipid syndrome. Circulation. 2010;122:e459–60.

    Article  PubMed  Google Scholar 

  37. Deo SV, Park SJ. Primary antiphospholipid antibody syndrome and Libmann–Sachs endocarditis. Mayo Clin Proc. 2011;86:929.

    Article  PubMed  Google Scholar 

  38. Shroff H, Benenstein R, Freedberg R, Mehl S, Saric M. Mitral valve Libman–Sacks endocarditis visualized by real time three-dimensional transesophageal echocardiography. Echocardiogr. 2012;29:E100–1.

    Article  Google Scholar 

  39. Roldan CA. Diagnostic value of transesophageal echocardiography in Libman–Sacks endocarditis. Minerva Cardioangiol. 2009;57:467–81.

    PubMed  CAS  Google Scholar 

  40. Schneider C, Bahlmann E, Antz M, et al. Images in cardiovascular medicine. Unusual manifestation of Libman–Sacks endocarditis in systemic lupus erythematosus. Circulation. 2003;107:e202–4.

    Article  PubMed  Google Scholar 

  41. Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. J Clin Rheumatol. 2006;12:3–10.

    Article  PubMed  Google Scholar 

  42. Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490–3.

    Article  PubMed  CAS  Google Scholar 

  43. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997;27:27–35.

    Article  PubMed  CAS  Google Scholar 

  44. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12:518–23.

    Article  PubMed  CAS  Google Scholar 

  45. Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33:168–81.

    Article  PubMed  Google Scholar 

  46. •• Erdozain JG, Ruiz-Irastorza G, Segura MI, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64:1256–60. In this retrospective study of patients undergoing cardiac valve surgery, Erdozain et al. revealed the very high-risk of these procedures for patients with APS in terms of thrombotic and bleeding complications.

    Google Scholar 

  47. Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127:414–20.

    Article  PubMed  Google Scholar 

  48. Colli A, Mestres CA, Espinosa G, et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37:154–8.

    Article  PubMed  Google Scholar 

  49. Hegde VA, Vivas Y, Shah H, et al. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome–a case-series. Heart Lung Circ. 2007;16:423–7.

    Article  PubMed  Google Scholar 

  50. Unger P, Plein D, Pradier O, LeClerc JL. Thrombosis of aortic valve homograft associated with lupus anticoagulant antibodies. Ann Thorac Surg. 2004;77:312–4.

    Article  PubMed  Google Scholar 

  51. Saito S, Ikeguchi H, Yamamoto H, Koike A, Yamaguchi K, Takeuchi E. Does antiphospholipid antibody syndrome affect bioprosthetic heart valve? midterm echocardiographic report. Jpn J Thorac Cardiovasc Surg. 2005;53:36–8.

    Article  PubMed  Google Scholar 

  52. Hogan WJ, McBane RD, Santrach PJ, et al. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc. 2000;75:971–6.

    Article  PubMed  CAS  Google Scholar 

  53. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford). 2000;39:421–6.

    Article  CAS  Google Scholar 

  54. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705–15.

    Article  PubMed  CAS  Google Scholar 

  55. Maisano F, La Canna G, Colombo A, Alfieri O. The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique. J Am Coll Cardiol. 2011;58:2174–82.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

Stéphane Zuily declares that he has no conflict of interest.

Olivier Huttin declares that he has no conflict of interest.

Shirine Mohamed declares that she has no conflict of interest.

Pierre-Yves Marie declares that he has no conflict of interest.

Christine Selton-Suty declares that she has no conflict of interest.

Denis Wahl declares that he has no conflict of interest.

Author information

Authors and Affiliations

  1. Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Centre Hospitalier Universitaire (CHU) Nancy, Nancy, 54000, France

    Stéphane Zuily, Shirine Mohamed & Denis Wahl

  2. Institut National de la Santé et de la Recherche Médicale (INSERM), U961, Nancy, 54000, France

    Stéphane Zuily & Denis Wahl

  3. Université de Lorraine, Nancy, 54000, France

    Stéphane Zuily & Denis Wahl

  4. Cardiology Departement, Centre Hospitalier Universitaire (CHU) Nancy, Nancy, 54000, France

    Olivier Huttin & Christine Selton-Suty

  5. Departement of nuclear medicine, Centre Hospitalier Universitaire (CHU) Nancy, Nancy, 54000, France

    Pierre-Yves Marie

  6. Unité de Médecine Vasculaire, Centre de Compétences Régional des Maladies Vasculaires Rares et Auto-Immunes, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, CHU Nancy, rue du Morvan, 54511, Vandoeuvre-lès-Nancy Cedex, France

    Stéphane Zuily, Shirine Mohamed & Denis Wahl

  7. Département de Cardiologie Médicale, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, CHU Nancy–Brabois, rue du Morvan, 54511, Vandoeuvre-lès-Nancy Cedex, France

    Olivier Huttin & Christine Selton-Suty

  8. Département médecine nucléaire, CHU Nancy–Brabois, rue du Morvan, 54511, Vandoeuvre-lès-Nancy Cedex, France

    Pierre-Yves Marie

Authors
  1. Stéphane Zuily
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Huttin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shirine Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre-Yves Marie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine Selton-Suty
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Denis Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denis Wahl.

Additional information

This article is part of the Topical Collection on Antiphospholipid Syndrome

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zuily, S., Huttin, O., Mohamed, S. et al. Valvular Heart Disease in Antiphospholipid Syndrome. Curr Rheumatol Rep 15, 320 (2013). https://doi.org/10.1007/s11926-013-0320-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0320-8

Keywords

Search

Navigation